Literature DB >> 2973436

Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation.

G J Cianciolo1, H Bogerd, R Snyderman.   

Abstract

Immunosuppression frequently accompanies infections with the human retroviruses HTLV-1 and HIV. Previous studies have shown that UV-inactivated and detergent-disrupted preparations of either virus can produce immune dysfunction in vitro although the active component of such preparations has not yet been identified. We now report that synthetic peptides corresponding to a conserved sequence within the transmembrane envelope proteins of both HTLV-1 (CS-1) and HIV (CS-3) are capable of suppressing the in vitro proliferative responses of human T lymphocytes to mitogenic or allogeneic stimulation. CS-1 inhibits proliferation in response to stimulation by anti-CD3 antibody by up to 57% a concentration of 3 nmol per culture well. CS-3 inhibits by up to 49% at a similar concentration. CS-1 and CS-3 inhibit two-way mixed leukocyte culture reactions by 81 and 88%, respectively, at the 3 nmol per well concentration. The inhibition by such human retrovirus-related peptides appears to be T cell-specific in that B cell proliferation in response to stimulation with anti-IgG is not affected by the CS-3 peptide. The release of such immunosuppressive peptides may thus play a role in the pathogenesis of human exogenous retroviral disease such as AIDS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973436     DOI: 10.1016/0165-2478(88)90112-5

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

1.  Inhibition of lymphoproliferation and protein kinase C by synthetic peptides with sequence identity to the transmembrane and Q proteins of visna virus.

Authors:  C L Ruegg; J E Clements; M Strand
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

2.  Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein.

Authors:  S B Tencza; M A Miller; K Islam; T A Mietzner; R C Montelaro
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

3.  Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.

Authors:  S A Hammond; S J Cook; D L Lichtenstein; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy.

Authors:  A Faith; R E O'Hehir; M Malkovsky; J R Lamb
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

5.  Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein.

Authors:  S Haraguchi; R A Good; M James-Yarish; G J Cianciolo; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

6.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Augmentation of c-fos and c-jun expression in transgenic mice carrying the human T-cell leukemia virus type-I tax gene.

Authors:  Y Iwakura; M Tosu; E Yoshida; S Saijo; J Nakayama-Yamada; K Itagaki; M Asano; H Siomi; M Hatanaka; T Takeda
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

8.  Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway.

Authors:  D Cefai; P Debre; M Kaczorek; T Idziorek; B Autran; G Bismuth
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 9.  Markers predicting progression of human immunodeficiency virus-related disease.

Authors:  C M Tsoukas; N F Bernard
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

10.  Biomarkers predicting progression of human immunodeficiency virus-related disease.

Authors:  Amar Kanekar
Journal:  J Clin Med Res       Date:  2010-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.